[go: up one dir, main page]

DE69724944D1 - Peptidverbindungen mit mmp- und tnf-hemmender wirkung - Google Patents

Peptidverbindungen mit mmp- und tnf-hemmender wirkung

Info

Publication number
DE69724944D1
DE69724944D1 DE69724944T DE69724944T DE69724944D1 DE 69724944 D1 DE69724944 D1 DE 69724944D1 DE 69724944 T DE69724944 T DE 69724944T DE 69724944 T DE69724944 T DE 69724944T DE 69724944 D1 DE69724944 D1 DE 69724944D1
Authority
DE
Germany
Prior art keywords
pct
compounds
mmp
subject invention
inhibiting effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69724944T
Other languages
English (en)
Other versions
DE69724944T2 (de
Inventor
Douglas Baxter
Alan Owen
Gary Montana
John Watson
Fraser Keily
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of DE69724944D1 publication Critical patent/DE69724944D1/de
Application granted granted Critical
Publication of DE69724944T2 publication Critical patent/DE69724944T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/32Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69724944T 1996-04-04 1997-04-04 Peptidverbindungen mit mmp- und tnf-hemmender wirkung Expired - Fee Related DE69724944T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9607249.1A GB9607249D0 (en) 1996-04-04 1996-04-04 Compounds
GB9607249 1996-04-04
PCT/GB1997/000959 WO1997037974A1 (en) 1996-04-04 1997-04-04 Peptidyl compounds having mmp and tnf inhibitory activity

Publications (2)

Publication Number Publication Date
DE69724944D1 true DE69724944D1 (de) 2003-10-23
DE69724944T2 DE69724944T2 (de) 2004-07-15

Family

ID=10791700

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724944T Expired - Fee Related DE69724944T2 (de) 1996-04-04 1997-04-04 Peptidverbindungen mit mmp- und tnf-hemmender wirkung

Country Status (9)

Country Link
US (1) US6090840A (de)
EP (1) EP0891329B1 (de)
JP (1) JP2000508640A (de)
AT (1) ATE250030T1 (de)
AU (1) AU713477B2 (de)
CA (1) CA2248070A1 (de)
DE (1) DE69724944T2 (de)
GB (1) GB9607249D0 (de)
WO (1) WO1997037974A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
FR2797890A1 (fr) * 1999-08-31 2001-03-02 Pf Medicament Nouvelle metalloprotease matricielle mmp-24 homologue aux stromelysines
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
EP3609877B1 (de) * 2017-04-14 2020-12-23 Cosma S.p.A. Verfahren zur herstellung von firocoxib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
AU713477B2 (en) 1999-12-02
EP0891329A1 (de) 1999-01-20
AU2302597A (en) 1997-10-29
CA2248070A1 (en) 1997-10-16
WO1997037974A1 (en) 1997-10-16
US6090840A (en) 2000-07-18
ATE250030T1 (de) 2003-10-15
EP0891329B1 (de) 2003-09-17
JP2000508640A (ja) 2000-07-11
GB9607249D0 (en) 1996-06-12
DE69724944T2 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
EP1119362A4 (de) Verwendungsmethode von tetracyclinverbindungen zur steigerung der interleukin-10 produktion
NZ335981A (en) Ketobenzamides as calpain inhibitors
PL319503A1 (en) Peptide compounds and their therapeutic application as inhibitors
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
EP1163208A4 (de) Caspase inhibitoren und deren verwendung
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
NO983438L (no) Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
DE69724944D1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
DE69928244D1 (de) Inhibitoren der nf-kb aktivierung
DE69724112D1 (de) Peptidverbindungen mit mmp- und tnf-hemmender wirkung
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
SE9802538D0 (sv) New pharmaceutically active compounds
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
DE69713611D1 (de) Verwendung von natrium 2-mercaptoethansulfonat in der chirurgie
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee